Apritant IV Injection contains Fosaprepitant Dimeglumine (150mg), a prodrug of Aprepitant, which is a neurokinin-1 (NK1) receptor antagonist used to prevent nausea and vomiting caused by chemotherapy. It works by blocking the action of substance P, a neurotransmitter that triggers the vomiting reflex. Apritant is typically administered intravenously 30 minutes before chemotherapy, especially in regimens involving highly or moderately emetogenic agents. It is used in combination with other antiemetics like dexamethasone and 5-HT3 antagonists for optimal protection against both acute and delayed chemotherapy-induced nausea and vomiting (CINV). Dosage: 150mg IV infusion over 20–30 minutes Indications: Prevention of CINV in adults and children ≥6 months Precautions: Use with caution in liver disease; not recommended during breastfeeding Common side effects: Headache, constipation, fatigue, injection site reactions
